Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia

Journal of the American College of Cardiology

Volumn 36, Issue 2, 2000, Pages 427-431

  Ferro, Domenico ^a   Parrotto, Sandro ^a   Basili, Stefania ^a   Alessandri, Cesare ^a   Violi, Francesco ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIET RESTRICTION; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; MALE; MONOCYTE; MULTIFACTORIAL INHERITANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTERLEUKIN-1; MALE; MIDDLE AGED; MONOCYTES; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033868728     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00771-3     Document Type: Article

References (31)

1. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease
2. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease
3. Range of serum cholesterol values in the population developing coronary artery disease
4. Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid
5. Helsinki Heart Study: Primary-prevention with gemfibrozil in middle-aged men with dyslipemia
6. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
7. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
8. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
9. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Study Group
10. Statins do more than just lower cholesterol
11. MAAS investigators. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS)
12. Atherosclerosis-an inflammatory disease
13. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
14. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia
15. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge
16. Increased procoagulant activity in peripheral blood mononuclear cells from patients with liver cirrhosis
17. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies
18. Monocyte tissue factor induction by lipopolysaccharide (1ps): Dependence on LPS-binding protein and cd14, and inhibition by a recombinant fragment of bactericidal/permeability-increasing protein
19. Raised serum levels of tumor necrosis factor in parasitic infections
20. Simvastatin reduces enhanced monocyte tissue factor expression in patients with type IIa hypercholesterolemia
21. Lipoproteins and the pathogenesis of atherosclerosis
22. Antioxidants and atherosclerotic heart disease
23. Macrophages, smooth muscle cells, and tissue factor in unstable angina
24. Tissue-factor antigen and activity in human coronary atherosclerotic plaque
25. P21ras is modified by a farnesyl isoprenoid
26. The post-translational modification of ras p21 is important for Raf-1 activation
27. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages
28. Regulation of manganese superoxide dismutase and other antioxidant genes in normal and leukemic hematopoietic cells and the relationship to cytotoxicity by tumor necrosis factor
29. Tissue factor and hemostasis